Clinical Trials Logo

Clinical Trial Summary

This study will assess the safety, tolerability, and pharmacokinetics of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior bilateral total ethmoidectomy.

Clinical Trial Description

LYR-220 is a combination product comprised of a drug matrix, which contains the anti-inflammatory medication mometasone furoate (MF) pre-loaded in a single use applicator. LYR-220 is intended to be placed bilaterally into the sino-nasal passages by an otolaryngologist. Once in place, each LYR-220 drug matrix is designed to gradually deliver sustained topical doses of MF to the inflamed mucosal sinus tissue over 24 weeks. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05035654
Study type Interventional
Source Lyra Therapeutics
Status Not yet recruiting
Phase Phase 2
Start date November 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT02668302 - The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant Phase 4
Recruiting NCT03472144 - Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis Phase 3